Business, energy, technology, markets and global industry news from Business News Today

Nicox SA

PharmaDeviceNews Nicox SA
A representative image illustrating NCX 470 glaucoma treatment research as the nitric oxide-donating eye drop enters regulatory review in China following two positive Phase 3 trials in glaucoma and ocular hypertension.
Pharma & Biotech

NCX 470 moves toward China approval with U.S. review already underway

NCX 470 enters China regulatory review after two positive Phase 3 glaucoma trials. Read why U.S. and China decisions could reshape Nicox.

Read More
Pharma & Biotech

What Nicox SA’s NCX 470 presentations signal for nitric oxide–based eye therapies

Discover how Nicox SA’s NCX 470 Phase 3 data could reshape glaucoma treatment and regulatory strategy. Read the full analysis.

Read More